A report for Medicines New Zealand.
This report, commissioned by Medicines New Zealand, found that clinical trials contributed $763 million to the New Zealand economy in 2025 and supported around 5,000 jobs, including 1,500 skilled roles in the sector. Much of this value stems from foreign investment. For patients, clinical trials provide earlier access to innovative treatments and care.
New Zealand’s clinical trials sector has real strengths that have attracted significant clinical trial investment. However, the sector survey conducted for this report indicates that New Zealand risks falling behind. Despite its growth potential, the sector is fragmented and has received limited government promotion or investment, whereas other countries such as Australia have explicitly recognised the value of this sector and are actively improving their incentives, infrastructure and international promotion to attract more trials.
The report identifies several ways New Zealand could protect and grow its clinical trials sector, including recognising trials as a source of foreign investment, strengthening R&D incentives and international promotion, establishing national coordination to improve collaboration between the public and private sectors, ensuring adequate resourcing for critical regulatory and ethics approval processes, and improving publicly funded access to modern medicines.